The Chemours Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for The Chemours in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" The Chemours stock.
View analyst ratings for The Chemours or view top-rated stocks.

Wall Street analysts have given The Chemours a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but The Chemours wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

The Chemours is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for The Chemours.

The Chemours will be holding an earnings conference call on Friday, July 30th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

The Chemours Company (NYSE:CC) released its quarterly earnings results on Sunday, May, 2nd. The specialty chemicals company reported $0.71 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.63 by $0.08. The specialty chemicals company earned $1.44 billion during the quarter, compared to analysts' expectations of $1.40 billion. The Chemours had a trailing twelve-month return on equity of 43.27% and a net margin of 4.25%. The business's revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.71 EPS.
View The Chemours' earnings history.

The Chemours' stock was trading at $10.66 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CC shares have increased by 201.9% and is now trading at $32.18.
View which stocks have been most impacted by COVID-19.

The Chemours declared a quarterly dividend on Thursday, April 29th. Stockholders of record on Monday, May 17th will be paid a dividend of $0.25 per share on Tuesday, June 15th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 3.11%. The ex-dividend date is Friday, May 14th.
View The Chemours' dividend history.

The Chemours pays an annual dividend of $1.00 per share and currently has a dividend yield of 3.13%. The Chemours does not yet have a strong track record of dividend growth. The dividend payout ratio of The Chemours is 50.51%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, The Chemours will have a dividend payout ratio of 26.60% next year. This indicates that The Chemours will be able to sustain or increase its dividend.
View The Chemours' dividend history.

The Chemours updated its FY 2021 earnings guidance on Monday, May, 17th. The company provided EPS guidance of 2.840-3.560 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.870. The company issued revenue guidance of -.

10 Wall Street analysts have issued 1-year price targets for The Chemours' shares. Their forecasts range from $28.00 to $48.00. On average, they expect The Chemours' share price to reach $37.22 in the next year. This suggests a possible upside of 15.7% from the stock's current price.
View analysts' price targets for The Chemours or view top-rated stocks among Wall Street analysts.

106 employees have rated The Chemours CEO Mark Vergnano on Glassdoor.com. Mark Vergnano has an approval rating of 85% among The Chemours' employees.

Some companies that are related to The Chemours include Asahi Kasei (AHKSY), FMC (FMC), Johnson Matthey (JMPLY), Olin (OLN), Huntsman (HUN), Ashland Global (ASH), W. R. Grace & Co. (GRA), Balchem (BCPC), Univar Solutions (UNVR), Showa Denko K.K. (SHWDY), Kuraray (KURRY), Ingevity (NGVT), Livent (LTHM), Innospec (IOSP) and PQ Group (PQG).
View all of CC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other The Chemours investors own include AT&T (T), Pfizer (PFE), DuPont de Nemours (DD), NVIDIA (NVDA), Cisco Systems (CSCO), Micron Technology (MU), Intel (INTC), AbbVie (ABBV), CVS Health (CVS) and Energy Transfer (ET).

The Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

The Chemours' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vaughan Nelson Investment Management L.P. (1.33%), Private Management Group Inc. (0.49%), Oregon Public Employees Retirement Fund (0.03%), New Mexico Educational Retirement Board (0.02%), Bristol John W & Co. Inc. NY (0.00%) and Raymond James Trust N.A. (0.00%). Company insiders that own The Chemours stock include Bradley J Bell, David C Shelton, E Bryan Snell, Edwin C Sparks, Mark Newman, Mark P Vergnano, Mary B Cranston, Matthew S Abbott and Richard H Brown.
View institutional ownership trends for The Chemours.

CC stock was sold by a variety of institutional investors in the last quarter, including Private Management Group Inc.. Company insiders that have sold The Chemours company stock in the last year include Edwin C Sparks, Mark P Vergnano, and Matthew S Abbott.
View insider buying and selling activity for The Chemours or view top insider-selling stocks.

CC stock was acquired by a variety of institutional investors in the last quarter, including Vaughan Nelson Investment Management L.P., Bristol John W & Co. Inc. NY, Raymond James Trust N.A., Brookstone Capital Management, New Mexico Educational Retirement Board, and Oregon Public Employees Retirement Fund. Company insiders that have bought The Chemours stock in the last two years include Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mary B Cranston, and Richard H Brown.
View insider buying and selling activity for The Chemours or or view top insider-buying stocks.

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CC stock can currently be purchased for approximately $32.18.

The Chemours has a market capitalization of $5.33 billion and generates $4.97 billion in revenue each year. The specialty chemicals company earns $219 million in net income (profit) each year or $1.98 on an earnings per share basis.

The Chemours employs 6,500 workers across the globe.

The official website for The Chemours is www.chemours.com.

The Chemours is headquartered at 1007 MARKET STREET, WILMINGTON DE, 19801.

The Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]